US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BioStem Technologies, Inc.

3.54

-0.1400-3.80%

Post-market: 3.53-0.0100-0.28%19:30 EDT

Volume:63.39K

Turnover:230.13K

Market Cap:63.12M

PE:-2.12

High:3.80

Open:3.69

Low:3.50

Close:3.68

52wk High:8.40

52wk Low:2.25

Shares:17.83M

Float Shares:14.12M

Volume Ratio:0.62

T/O Rate:0.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6713

EPS(LYR):-0.3934

ROE:-74.74%

ROA:-18.07%

PB:2.29

PE(LYR):-9.00

Loading ...

Overview Company News Filings

Press Release: BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer

Biostem Strengthens Leadership Team With Appointment of Katherine Gorrell as Chief Legal & Compliance Officer

THOMSON REUTERS

Press Release: BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025

Press Release: BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BSEM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSEM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEM\",,,,,undefined,":{"symbol":"BSEM","market":"US","secType":"STK","nameCN":"BioStem Technologies, Inc.","latestPrice":3.54,"timestamp":1787342400000,"preClose":3.68,"halted":0,"volume":63391,"hourTrading":{"tag":"盘后","latestPrice":3.53,"preClose":3.54,"latestTime":"19:30 EDT","volume":623,"amount":2189.92,"timestamp":1787355004815,"change":-0.01,"changeRate":-0.002825,"amplitude":0.008475},"delay":0,"changeRate":-0.038043478260869595,"floatShares":14116616,"shares":17831900,"eps":-1.671347,"marketStatus":"Market Closed","change":-0.14,"latestTime":"08-21 16:00:00 EDT","open":3.69,"high":3.8,"low":3.5,"amount":230130.8766009,"amplitude":0.081522,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.671347,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":3.68,"preHourTrading":{"tag":"盘前","latestPrice":3.69,"preClose":3.68,"latestTime":"09:29 EDT","volume":911,"amount":3386.9000397,"timestamp":1787318994706,"change":0.01,"changeRate":0.002717,"amplitude":0.021739},"postHourTrading":{"tag":"盘后","latestPrice":3.53,"preClose":3.54,"latestTime":"19:30 EDT","volume":623,"amount":2189.92,"timestamp":1787355004815,"change":-0.01,"changeRate":-0.002825,"amplitude":0.008475},"volumeRatio":0.6222832587228262},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEM\",,,,,undefined,":{"symbol":"BSEM","floatShares":14116616,"roa":"-18.07%","roe":"-74.74%","lyrEps":-0.393388,"volumeRatio":0.6222832587228262,"shares":17831900,"dividePrice":0,"high":3.8,"amplitude":0.081522,"preClose":3.68,"low":3.5,"week52Low":2.251,"pbRate":"2.29","psRate":"1.83","week52High":8.4,"institutionHeld":0,"latestPrice":3.54,"eps":-1.671347,"divideRate":0,"volume":63391,"delay":0,"ttmEps":-1.671347,"open":3.69,"prevYearClose":3.81,"prevWeekClose":3.21,"prevMonthClose":3.3142,"prevQuarterClose":3.3,"fiveDayClose":3.21,"twentyDayClose":4.01,"sixtyDayClose":3.988},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSEM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"BSEM","fiscalQuarterEnding":"2026/06","expectedEps":-0.5,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.52},{"date":"2026-05-14","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1778788800000,"name":null,"time":"Post-Mkt","dateTimestamp":1778731200000,"actualEps":null},{"date":"2026-03-24","symbol":"BSEM","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774339200000,"name":null,"time":"","dateTimestamp":1774324800000,"actualEps":null},{"date":"2025-11-13","symbol":"BSEM","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763024400000,"name":null,"time":"","dateTimestamp":1763010000000,"actualEps":null},{"date":"2025-08-14","symbol":"BSEM","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755158400000,"name":null,"time":"","dateTimestamp":1755144000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSEM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BSEM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1778126400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BSEM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BSEM","date":"2026-08-21","current":-2.118052,"percent":0.5,"low":-3.757423,"twenty":-3.470255,"median":-2.321824,"eighty":-1.987431,"high":-1.892791,"avg":-2.677618,"sd":0.700647,"marketCap":65686053},"quantilePoints":[{"date":"2026-08-06","current":-3.060802,"twenty":-3.060802,"median":-3.060802,"eighty":-3.060802,"marketCap":59100221},{"date":"2026-08-14","current":-1.982708,"twenty":-3.488616,"median":-3.39222,"eighty":-3.060802,"marketCap":54952215},{"date":"2026-08-21","current":-2.321824,"twenty":-3.470255,"median":-2.321824,"eighty":-1.987431,"marketCap":65686053}],"updateTime":1787454963756},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSEM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631636324","title":"Press Release: BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636324","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636324?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:08","pubTimestamp":1777547280,"startTime":"0","endTime":"0","summary":"POMPANO BEACH, Fla., April 30, 2026  -- BioStem Technologies , a leading regenerative medicine company focused on the development, manufacturing and commercialization of perinatal tissue allograft products, today announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026.Ms. Gorrell has an extensive career advising hospital systems and health technology companies, with deep experience in health law, regulatory, transactional, compliance, governance, and risk management, as well as other business-oriented legal functions that facilitate strategic expansion and ensure operational excellence. In her role, she will oversee BioStem's legal and compliance functions and play a central role in enterprise governance, including the integration and oversight of Medical Affairs through BioStem's compliance framework.\"Katherine is a key addition to BioStem as we implement our next phase of growth,\" said Jason Matuszewski, Chairman and CEO of BioStem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BSEM","R","03160","BK4120","BK4022","TISI","BK4555","BK4604","BK4585","TM","BK4588","BK4007","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631635813","title":"Biostem Strengthens Leadership Team With Appointment of Katherine Gorrell as Chief Legal & Compliance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2631635813","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631635813?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA72V02Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BSEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311986","title":"Press Release: BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311986","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311986?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:02","pubTimestamp":1774868520,"startTime":"0","endTime":"0","summary":"POMPANO BEACH, Fla., March 30, 2026  -- BioStem Technologies, Inc. , a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has filed its audited consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2025. The financial statements are available for review in their entirety on the OTC Markets website here. With the publication of the audited consolidated financial statements, BioStem has taken another significant step toward a Nasdaq uplisting.\"We are pleased to have published our audited financial statements for 2024 and 2025, which marks an important milestone for the Company. Along with the appointment of a new CFO, auditor and audit committee chair, this achievement highlights the significant effort we have made to establish robust financial reporting processes and positions the Company to advance our corporate initiatives, includin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4555","BSEM","BK4588","BK4007","BK4022","BK4585","TM","BK4099","03160","BK4232","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089777","title":"Press Release: BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089777","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621089777?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:04","pubTimestamp":1774263840,"startTime":"0","endTime":"0","summary":"POMPANO BEACH, Fla., March 23, 2026  -- BioStem Technologies , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Jodi Ungrodt to its Board of Directors, where she will also serve as Chair of the Audit Committee, effective March 18, 2026.\"I am excited to welcome Jodi to our board as we undertake this expansion of our business beyond chronic wound care,\" said Jason Matuszewski, Chairman and CEO of BioStem Technologies. \"Along with the business expansion, we also plan to raise our profile in the public markets in 2026. Jodi's twenty-nine years of life sciences accounting experience at Ernst & Young, along with her track record advising more than thirty IPOs and deep regulatory and government expertise, will make a terrific addition to our board governance during this pivotal time.\". Ungrodt holds a BS in Accounting from San Diego State University and is a Cert","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","TM","BK4099","BK4022","BK4604","BK4007","BK4588","BSEM","BK4232","03160","BK4585","R"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":24,"code":"91000000","status":"200"}]}}